2024
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Shroff R, King G, Colby S, Scott A, Borad M, Goff L, Matin K, Mahipal A, Kalyan A, Javle M, Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie K, Chiorean E, Hochster H, Philip P. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Journal Of Clinical Oncology 2024, 43: 536-544. PMID: 39671534, PMCID: PMC11798714, DOI: 10.1200/jco-24-01383.Peer-Reviewed Original ResearchProgression-free survivalBiliary tract cancerAdvanced biliary tract cancerOverall survivalGallbladder carcinomaExtrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaHazard ratioNab-paclitaxelMedian progression-free survivalMetastatic biliary tract cancerProgression-free survival benefitPhase III randomized trialGemcitabine-cisplatin regimenTrial of gemcitabineLocally advanced diseaseExploratory subset analysisDiagnosing BTCEvaluated gemcitabineMedian OSMetastatic diseaseAdvanced diseaseNo significant differenceSubset analysisGemcitabineAB042. Deep dive into the NEJM study suggesting health consequences after thymectomy
Detterbeck F, Kaminski H. AB042. Deep dive into the NEJM study suggesting health consequences after thymectomy. Mediastinum 2024, 8: ab042-ab042. PMCID: PMC11736237, DOI: 10.21037/med-24-ab042.Peer-Reviewed Original ResearchInternational Thymic Malignancy Interest GroupAutoimmune diseasesWorse survivalAssociated with more aggressive cancersAssociated with worse survivalPrimary analysisCardiac surgery cohortImmune function markersBasic science dataSecondary analysisIncidence of cancerHealth consequencesSurgery cohortCardiac surgeryEndpoint of survivalPatient subsetsThymic involutionSubset analysisAggressive cancerThymectomyTertiary analysisEndpoint definitionsComparator cohortMatched ControlsPatientsRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-FreePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsPhase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Chavez-MacGregor M, Miao J, Pusztai L, Goetz M, Rastogi P, Ganz P, Mamounas E, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber A, Flaum L, Andreopoulou E, Wendt A, Carney J, Sharma P, Gralow J, Lew D, Barlow W, Hortobagyi G. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer. Journal Of Clinical Oncology 2024, 42: 3012-3021. PMID: 38833643, PMCID: PMC11565489, DOI: 10.1200/jco.23.02344.Peer-Reviewed Original ResearchInvasive disease-free survivalHormone receptor-positiveEndocrine therapyOverall survivalBreast cancerHazard ratioReceptor-positiveHigh riskSubset analysisHormone receptor-positive metastatic breast cancerRisk groupsHormone receptor-positive BCEarly-stage breast cancerStratified log-rank testProgression-free survivalEfficacy of everolimusDisease-free survivalMetastatic breast cancerPlacebo-controlled trialSecondary end pointsLog-rank testHighest grade 3Treatment completion ratesPhase IIIEverolimus arm
2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt A, Rich P, Sofen H, Strober B, Merola J, Lebwohl M, Morita A, Szepietowski J, Lambert J, Hippeli L, Colston E, Balagula E, Banerjee S, Thaçi D. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. Journal Of The American Academy Of Dermatology 2023, 90: 775-782. PMID: 38122848, DOI: 10.1016/j.jaad.2023.11.060.Peer-Reviewed Original ResearchPsoriasis Scalp Severity IndexSevere scalp psoriasisScalp psoriasisPlaque psoriasisSeverity IndexWeek 16Physician's Global Assessment 0/1Physician Global Assessment scoreGlobal phase 3Double-blinded trialEntire study populationGlobal assessment scorePhase 3Pooled secondary analysisOral placeboScalp involvementSevere psoriasisAdverse eventsSubset analysisStudy populationPsoriasisDeucravacitinibResponse rateSecondary analysisPlaceboPhysician Assistant Gender Differences in Research, Professional Goals, and Perceptions of Support
Lolar S, Welch R, Garino A. Physician Assistant Gender Differences in Research, Professional Goals, and Perceptions of Support. The Journal Of Physician Assistant Education 2023, 35: 94-100. PMID: 37878608, DOI: 10.1097/jpa.0000000000000551.Peer-Reviewed Original ResearchCross-sectional studyPercent of menPercent of respondentsSubset analysisResponse rateStatistical differenceWomenConfidence intervalsPA programsAnonymous surveyMenStratified random sampling methodPromotion goalsRandom sampling methodGender differencesStratified sample designPerceptions of supportPercent
2021
Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection
Fonseca RB, Straub Hogan MM, Kapp ME, Cate F, Coogan A, Arora S, Gordetsky J, Smelser WW, Clark PE, Cates J, Giannico GA. Diagnostic renal mass biopsy is associated with individual categories of PADUA and RENAL nephrometry scores: Analysis of diagnostic and concordance rates with surgical resection. Urologic Oncology Seminars And Original Investigations 2021, 39: 371.e7-371.e15. PMID: 33773915, PMCID: PMC8205938, DOI: 10.1016/j.urolonc.2021.02.022.Peer-Reviewed Original ResearchConceptsCore needle biopsySmall renal massesFine-needle aspirationRenal mass biopsyDiagnostic core needle biopsyDiagnostic fine needle aspirationRenal massesNon-diagnostic rateCystic massMass biopsyConcordance rateEndophytic growthRenal sinus invasionRENAL nephrometry scoreSurgical resection specimensSurgical resectionNephrometry scoreSinus invasionRetrospective studyPreoperative aspectsResection specimensSingle institutionClinical managementSubset analysisNeedle biopsyGaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment
Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, investigators F. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Molecular Genetics And Metabolism 2021, 132: 100-111. PMID: 33485799, DOI: 10.1016/j.ymgme.2020.12.295.Peer-Reviewed Original ResearchConceptsBone painNon-splenectomized patientsType 1 patientsBone crisesPlatelet countLiver volumeSubset analysisBody mass index (BMI) outcomesGaucher diseaseEarly treatment yearsInitial clinical improvementDifferent patient subsetsPre-treatment baselineLong-term treatmentEnzyme replacement therapyICGG Gaucher RegistryGD type 1 patientsImiglucerase treatmentAdult patientsClinical improvementSplenectomy statusGaucher RegistryPatient subsetsTreatment initiationNormal weight
2020
An Evaluation of Health Numeracy among Radiation Therapists and Dosimetrists
Peters GW, Kelly JR, Beckta JM, White M, Marks LB, Ford E, Evans SB. An Evaluation of Health Numeracy among Radiation Therapists and Dosimetrists. Advances In Radiation Oncology 2020, 6: 100609. PMID: 34027232, PMCID: PMC8134660, DOI: 10.1016/j.adro.2020.10.022.Peer-Reviewed Original ResearchGeneral populationHealth numeracyHealth care professionalsEligible participantsSubset analysisStudy groupCare professionalsOncology professionalsMedian scoreLimited sample sizeRadiation oncologyRadiation therapistsMedical errorsAmerican SocietyScoresWhitney testDose unitsRange of scoresCohortRadiation oncology professionalsLower scoresSpearman's rhoMedicine instrumentsSample sizeAverage scoreMetabolic Syndrome, Exercise, and Cardiovascular Fitness in Breast Cancer Survivors
Knobf MT, Jeon S. Metabolic Syndrome, Exercise, and Cardiovascular Fitness in Breast Cancer Survivors. Journal Of The Advanced Practitioner In Oncology 2020, 11: 98-102. PMID: 33542853, PMCID: PMC7517769, DOI: 10.6004/jadpro.2020.11.1.6.Peer-Reviewed Original ResearchBreast cancer survivorsCancer survivorsRisk factorsMetabolic syndromeBlood sugarCardiovascular fitnessMetS risk factorsRisk of comorbiditiesSystolic blood pressurePhysical activity groupEffects of exerciseOncology Advanced PractitionersPoor cancer outcomesRoutine physical activityHigh-density lipoproteinIndividual risk factorsComorbid illnessesExercise interventionMetS riskBlood pressureWaist circumferenceOncology patientsCancer outcomesSubset analysisPhysical activity
2019
Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors
Torabi SJ, Spock T, Cardoso B, Chao J, Manes RP, Judson BL. Multi-modality Treatment and Survival in Sinonasal Minor Salivary Gland Tumors. Journal Of Neurological Surgery Part B Skull Base 2019, 81: 198-205. PMID: 32206540, PMCID: PMC7082160, DOI: 10.1055/s-0039-1683437.Peer-Reviewed Original ResearchMinor salivary gland tumorsSalivary gland tumorsTriple-modality therapyGland tumorsModality therapyMultimodality treatmentPositive marginsTreatment modalitiesSubset analysisNational Comprehensive Cancer Network guidelinesClinical American Joint CommitteeNational Cancer DatabaseMulti-modality treatmentOnly treatment modalityAmerican Joint CommitteeMost treatment modalitiesAdjuvant chemoradiotherapySurvival benefitSurgical managementNetwork guidelinesCancer DatabaseChemoradiotherapyCommon treatmentSurgeryJoint Committee
2018
Pediatric facial injuries: Hitting close to home
Youssef P, Povolotskiy R, Mukherjee TJ, Kandinov A, Paskhover B. Pediatric facial injuries: Hitting close to home. Journal Of Cranio-Maxillofacial Surgery 2018, 46: 1539-1543. PMID: 30196858, DOI: 10.1016/j.jcms.2018.05.054.Peer-Reviewed Original ResearchConceptsNational Electronic Injury Surveillance SystemFacial fracturesED visitsConsumer Product Safety CommissionAge groupsPreventative opportunitiesEmergency departmentNational incidenceElectronic Injury Surveillance SystemChallenging patient populationChildren 1 monthInjury Surveillance SystemCause of injuryMonths-5 yearsPlayground equipmentYears of ageType of fracturePatient demographicsRetrospective reviewNasal fracturesPatient populationClinical historyPrimary diagnosisSubset analysisCommon cause
2017
Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.Peer-Reviewed Original ResearchConceptsSecond primary tumorsOverall survivalFormer smokersDevelopment of SPTsIncidence of SPTsEarly-stage SCCHNFuture prevention trialsImproved overall survivalClinical risk factorsSquamous cell cancerLog-rank testLong-term resultsPotential survival advantageCompeting-risk approachCumulative incidenceIndex tumorCell cancerPrevention trialsPrimary tumorRisk factorsSubset analysisDry skinSurvival advantagePatientsTargeted interventions
2016
Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes
Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeRAEB patientsMedian survivalClinical trialsMultivariate Cox proportional hazards modelCox proportional hazards modelKaplan-Meier methodPopulation-based survivalSignificant survival differenceComparative clinical effectivenessProportional hazards modelAgent azacitidineHMA initiationExcess blastsOlder patientsRandomized trialsHistological subtypesRefractory anemiaClinical effectivenessSurvival differencesSubset analysisSurvival advantageHazards modelPatientsDecitabineThe Association Between Physician Empathy and Variation in Imaging Use
Melnick ER, O'Brien EG, Kovalerchik O, Fleischman W, Venkatesh AK, Taylor RA. The Association Between Physician Empathy and Variation in Imaging Use. Academic Emergency Medicine 2016, 23: 895-904. PMID: 27343485, PMCID: PMC5884096, DOI: 10.1111/acem.13017.Peer-Reviewed Original ResearchConceptsCT utilizationEmergency physician performanceEmergency physiciansPhysician performanceCT utilization ratesEmergency Department CTPhysician survey respondentsPatient-level variablesCross-sectional studyCohort of physiciansPhysician empathyLarge health systemPsychometric testsMixed effects regression modelsPhysician-based factorsPsychometric scalesSurvey response rateAcademic EDSubset analysisPhysician demographicsHead CTInterphysician variationResponse rateImaging useRTS scoreBiomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC.
Hirsch F, Redman M, Herbst R, Kim E, Semrad T, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold S, Varella-Garcia M, Moon J, Mack P, Blanke C, Kelly K, Gandara D. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal Of Clinical Oncology 2016, 34: 9090-9090. DOI: 10.1200/jco.2016.34.15_suppl.9090.Peer-Reviewed Original Research
2015
Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base
Rutter CE, Park HS, Corso CD, Lester-Coll NH, Mancini BR, Yeboa DN, Johung KL. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base. Cancer 2015, 121: 4141-4149. PMID: 26280559, DOI: 10.1002/cncr.29652.Peer-Reviewed Original ResearchConceptsImproved overall survivalNational Cancer Data BaseOverall survivalPancreatic adenocarcinomaAdjuvant chemotherapyR0 resectionR1 resectionPN1 diseaseNational cohortSubset analysisPropensity scoreAddition of radiotherapyMedian radiotherapy doseOutcome of chemotherapyLarge national cohortPT1-3N0CRT groupClinicopathologic characteristicsCRT patientsRandomized comparisonCox regressionRadiotherapy doseOptimal treatmentPancreatic cancerUnivariate analysis
2014
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis
Papp K, Menter A, Strober B, Kricorian G, Thompson E, Milmont C, Nirula A, Klekotka P. Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal Of The American Academy Of Dermatology 2014, 72: 436-439.e1. PMID: 25553889, DOI: 10.1016/j.jaad.2014.10.026.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBiologic useHistory of PsAPlaque psoriasisDermatology Life Quality Index responseStatic Physician's Global Assessment scorePhysician Global Assessment scoreSafety of brodalumabPlacebo-controlled studySubgroup of patientsSeverity Index scoreSubpopulation of patientsGlobal assessment scoreSelf-reported historyPrior biologicsTreat populationPsoriasis AreaPsoriatic arthritisWeek 12Subset analysisNovel therapiesBrodalumabLife measuresPatientsPsoriasisBenchmarking of Trauma Care Worldwide: The Potential Value of an International Trauma Data Bank (ITDB)
Haider A, Hashmi Z, Gupta S, Zafar S, David J, Efron D, Stevens K, Zafar H, Schneider E, Voiglio E, Coimbra R, Haut E. Benchmarking of Trauma Care Worldwide: The Potential Value of an International Trauma Data Bank (ITDB). World Journal Of Surgery 2014, 38: 1882-1891. PMID: 24817407, DOI: 10.1007/s00268-014-2629-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBenchmarkingDatabases, FactualDeveloped CountriesDeveloping CountriesFeasibility StudiesFemaleFranceGlobal HealthHospital MortalityHumansLogistic ModelsMaleMiddle AgedPakistanRegistriesTrauma CentersWounds, NonpenetratingWounds, PenetratingYoung AdultConceptsTrauma Data BankTrauma mortalityTrauma centerMortality ratioTrauma outcomesNational Trauma Data BankTrauma dataE mortality ratioNational Trauma RegistryMultivariable logistic regressionBlunt/Worse survivalTrauma registrySubset analysisPatient outcomesTrauma carePatientsLMIC centerLogistic regressionKey covariatesOutcomesInjuryMortalityPredictorsSimilar resultsDeveloping best practices to study trauma outcomes in large databases
Haider A, Hashmi Z, Zafar S, Castillo R, Haut E, Schneider E, Cornwell E, Mackenzie E, Efron D. Developing best practices to study trauma outcomes in large databases. Journal Of Trauma And Acute Care Surgery 2014, 76: 1061-1069. PMID: 24662872, DOI: 10.1097/ta.0000000000000182.Peer-Reviewed Original ResearchConceptsNational Trauma Data BankRisk-adjustment modelsTrauma mortalityTrauma outcomesSubsequent multivariate logistic regression analysisMultivariate logistic regression analysisManual backward selectionTrauma Data BankUnivariate logistic regressionLogistic regression analysisInitial multivariate modelPatient subsetsMultivariable analysisTrauma centerMortality outcomesSimilar AUROCsSubset analysisUnivariate analysisPrognostic studiesAnalytic standardizationLevel IIILogistic regression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply